Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Oct 26;61(11):1920.
doi: 10.3390/medicina61111920.

Comparison of Cryoballoon Ablation Methods in Pulmonary Vein Isolation

Affiliations
Comparative Study

Comparison of Cryoballoon Ablation Methods in Pulmonary Vein Isolation

Kaspars Kupics et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Cryoballoon ablation is a well-established therapy for atrial fibrillation (AF), enabling pulmonary vein isolation (PVI) using a single-shot technique. The two primary systems-Medtronic Arctic Front and the newer Boston Scientific POLARx-differ in design and performance characteristics, but few direct comparisons exist. This study aimed to compare the biophysical parameters and mid-term outcomes of the POLARx and Arctic Front cryoballoon systems. Materials and Methods: In a retrospective analysis of 200 patients who underwent cryoballoon ablation for paroxysmal or persistent AF, patients were grouped by ablation system: POLARx (n = 107) and Arctic Front (n = 93). Key parameters including nadir balloon temperatures, time to reach -40 °C, procedure duration, dose area product (DAP), complication rates, and recurrence of AF were assessed. Results: The POLARx system achieved significantly lower nadir temperatures in all pulmonary veins compared to Arctic Front (left superior PV: -57.6 ± 5.0 °C vs. -50.1 ± 5.7 °C, p < 0.001). Time to reach -40 °C was also shorter with POLARx (left superior PV: 23.3 ± 7.3 s vs. 33.3 ± 11.5 s, p < 0.001). Despite these advantages, procedure time was longer in the POLARx group (64.7 ± 14.8 min vs. 51.6 ± 19.7 min, p < 0.001). AF recurrence at 11.8 months was similar (33.6% in POLARx vs. 39.8% in Arctic Front, p = 0.93). Phrenic nerve palsy occurred in 5.0% (POLARx) and 4.3% (Arctic Front), with no cases of cardiac tamponade. Conclusions: While both systems demonstrated similar efficacy and safety, POLARx was associated with superior cooling kinetics and biophysical performance.

Keywords: atrial fibrillation; cryoballoon ablation; pulmonary vein isolation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Freezing characteristics of each pulmonary vein on a time–temperature graph. The blue-colored lines refer to Boston Scientific POLARx (labeled as 1), while the green-colored lines refer to Medtronic Arctic Front (labeled as 2). LSPV—left superior pulmonary vein; LIPV—left inferior pulmonary vein; RSPV—right superior pulmonary vein; RIPV—right inferior pulmonary vein. The POLARx system achieved a steeper temperature drop within a shorter time than the Arctic Front system frame across all veins within the same freezing duration, reflecting quicker cooling dynamics.

References

    1. Van Gelder I.C., Rienstra M., Bunting K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M., De Potter T.J.R., Dwight J., Guasti L., Hanke T., et al. 2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO) Eur. Heart J. 2024;45:3314–3414. doi: 10.1093/eurheartj/ehae176. - DOI - PubMed
    1. Linz D., Gawalko M., Betz K., Hendriks J.M., Lip G.Y.H., Vinter N., Guo Y., Johnsen S. Atrial Fibrillation: Epidemiology, Screening and Digital Health. Lancet Reg. Health Eur. 2024;37:100786. doi: 10.1016/j.lanepe.2023.100786. - DOI - PMC - PubMed
    1. Hachem A.H., Marine J.E., Tahboub H.A., Kamdar S., Kanjwal S., Soni R., Kanjwal K. Radiofrequency Ablation versus Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation: A Meta-Analysis. Cardiol. Res. Pract. 2018;2018:6276241. doi: 10.1155/2018/6276241. - DOI - PMC - PubMed
    1. Cheng S., He J., Han Y., Han S., Li P., Liao H., Guo J. Global Burden of Atrial Fibrillation/Atrial Flutter and Its Attributable Risk Factors from 1990 to 2021. EP Eur. 2024;26:euae195. doi: 10.1093/europace/euae195. - DOI - PMC - PubMed
    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.-A., Dilaveris P.E., et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612. - DOI - PubMed

Publication types

LinkOut - more resources